Elicio Therapeutics (ELTX) Common Equity (2020 - 2026)

Elicio Therapeutics (ELTX) has reported Common Equity for 7 consecutive years, with $7.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 332.77% year-over-year to $7.9 million; the trailing twelve-month figure through Jun 2026 stood at $7.9 million (up 332.77% YoY), and the FY2025 full-year result was $1.6 million, up 114.46% from the prior year.
• Common Equity advanced to $7.9 million in Q2 2026 per ELTX's latest filing, from -$1.4 million in the prior quarter.
• Across five years, Common Equity topped out at $23.6 million in Q2 2023 and bottomed at -$109.9 million in Q1 2023.
• Historically, Common Equity has averaged -$24.1 million across 5 years, with a median of $99500.0 in 2025.
• The sharpest annual moves came in 2022 and 2026: Common Equity tumbled 248.34% in 2022, then jumped 332.77% in 2026.
• Over 5 years, Common Equity stood at -$102.1 million in 2022, then soared by 111.13% to $11.4 million in 2023, then slumped by 199.46% to -$11.3 million in 2024, then surged by 114.46% to $1.6 million in 2025, then soared by 385.15% to $7.9 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $7.9 million, -$1.4 million, and $1.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.